Using this grafting method, the anti-HER2 humanized antibody trastuzumab was produced and FDA approved in 1998 to treat HER2-positive cancers (breast, pancreas, and non-small cell of lung cancer) [76]. Here, ERBB2 is linked to non-small cell lung carcinoma.